Interim analysis of phase III CheckMate-648 trial finds nivolumab (NV) with chemotherapy (CH) or ipilimumab (IP) demonstrated overall survival (OS) benefit compared to chemotherapy alone in advanced/metastatic oesophageal cancer

In the all-randomised patient population, NV plus CH demonstrated median OS of 13.2 months vs. 10.7 months for CH alone (12.8 months for NV plus IP vs 10.7 months for CH). Corresponding values in PD-L1 tumour population were 15.4 vs. 9.1 months and 13.7 vs. 9.1 months.

Source:

PharmaTimes